Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CTSK | P43235 | 7/20 | 0.35 |
| ▸ | CTSL | P07711 | 3/20 | 0.33 |
| ▸ | CTSB | P07858 | 3/20 | 0.33 |
| ▸ | CTSH | P09668 | 2/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13996915 | 0.98 | MEN1 (0.40) | MEN1KMT2ACTSKCTSLCTSB | |
| SCHEMBL25589751 | 0.98 | MEN1 (0.40) | MEN1KMT2ACTSKCTSLCTSB | |
| SCHEMBL25589752 | 0.96 | MEN1 (0.35) | MEN1KMT2ACTSKCNR2 | |
| SCHEMBL25589753 | 0.94 | MEN1 (0.33) | MEN1KMT2ACNR2 | |
| SCHEMBL25590340 | 0.81 | MEN1 (0.39) | MEN1KMT2ACTSKCTSLCTSB | |
| SCHEMBL24530159 | 0.81 | MEN1 (0.39) | MEN1KMT2ACTSKCTSLCTSB | |
| SCHEMBL23970178 | 0.79 | MEN1 (0.41) | MEN1KMT2ACTSKCTSLCTSB | |
| SCHEMBL4716380 | 0.79 | MEN1 (0.41) | MEN1KMT2ACTSKCTSLCTSB | |
| SCHEMBL25950011 | 0.79 | MEN1 (0.38) | MEN1KMT2ACTSKCTSLCTSB | |
| SCHEMBL16203420 | 0.79 | MEN1 (0.41) | MEN1KMT2ACTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167104-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2023-06-01 | — | — | US | disclosed |
| EP-3904354-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | Perha Pharmaceuticals (FR) | 2021-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167104-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | CLK1, CLK2, CLK3 | MEN1 1197/4885KMT2A 1484/4885CTSK 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.